Key result
A novel prognostic risk score was created to evaluate the efficacy of eplerenone across different risk categories in patients with systolic heart failure and mild symptoms.
Key points are not available for this paper at this time.
May inform eplerenone use by risk strata in mild systolic HF; extends RCT evidence to prognostic subgroups.
Our objective was to create a simple prognostic risk score for patients with systolic heart failure and mild symptoms. We then assessed the efficacy of eplerenone across different categories of risk.
No takes yet. Share an insight, caveat, or question.
Collier et al. (2013) studied this question. A novel prognostic risk score was created to evaluate the efficacy of eplerenone across different risk categories in patients with systolic heart failure and mild symptoms.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: